JP2020530302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530302A5 JP2020530302A5 JP2020507609A JP2020507609A JP2020530302A5 JP 2020530302 A5 JP2020530302 A5 JP 2020530302A5 JP 2020507609 A JP2020507609 A JP 2020507609A JP 2020507609 A JP2020507609 A JP 2020507609A JP 2020530302 A5 JP2020530302 A5 JP 2020530302A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- clec9a
- clec9a binding
- appendix
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 34
- 230000008685 targeting Effects 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 19
- 210000004443 dendritic cell Anatomy 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 241000251730 Chondrichthyes Species 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102220467431 Protein Jade-1_R35A_mutation Human genes 0.000 claims description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 102220521895 THAP domain-containing protein 1_L32A_mutation Human genes 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000000220 brain stem cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 102220067601 rs150464212 Human genes 0.000 claims description 2
- 102220008221 rs199476324 Human genes 0.000 claims description 2
- 102220065721 rs750676165 Human genes 0.000 claims description 2
- 102200072502 rs869025313 Human genes 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000004435 urinary system cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000006444 vascular growth Effects 0.000 claims 1
- 238000012552 review Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 101000888548 Homo sapiens C-type lectin domain family 9 member A Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 229930193936 anticarin Natural products 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- 108010030351 DEC-205 receptor Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000056371 human CLEC9a Human genes 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 208000013580 immune epilepsy Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007235 immunity generation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023033005A JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542944P | 2017-08-09 | 2017-08-09 | |
| US62/542,944 | 2017-08-09 | ||
| PCT/US2018/045742 WO2019032662A1 (en) | 2017-08-09 | 2018-08-08 | CLEC9A BINDING AGENTS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033005A Division JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530302A JP2020530302A (ja) | 2020-10-22 |
| JP2020530302A5 true JP2020530302A5 (enExample) | 2021-09-16 |
| JP7327885B2 JP7327885B2 (ja) | 2023-08-16 |
Family
ID=65272496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507609A Active JP7327885B2 (ja) | 2017-08-09 | 2018-08-08 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2023033005A Active JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A Active JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033005A Active JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A Active JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12091463B2 (enExample) |
| EP (1) | EP3665303A4 (enExample) |
| JP (3) | JP7327885B2 (enExample) |
| KR (3) | KR20250049459A (enExample) |
| CN (2) | CN117924493A (enExample) |
| AU (2) | AU2018313810B2 (enExample) |
| BR (1) | BR112020002706A2 (enExample) |
| CA (1) | CA3069992A1 (enExample) |
| IL (1) | IL272524A (enExample) |
| MX (3) | MX2020001513A (enExample) |
| SG (1) | SG11202001063QA (enExample) |
| WO (1) | WO2019032662A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020008208A (es) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Agentes de unión a fibroblastos y uso de estos. |
| CN111212661B (zh) * | 2018-09-11 | 2023-09-12 | 北京泰德制药股份有限公司 | 白介素-2多肽偶联物及其用途 |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP4034146A4 (en) * | 2019-09-26 | 2024-03-06 | Orionis Biosciences, Inc. | CONJUGATED CHIMERIC PROTEINS |
| AU2020398327A1 (en) | 2019-12-03 | 2022-07-14 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| KR20210129489A (ko) | 2020-04-20 | 2021-10-28 | 에스케이이노베이션 주식회사 | 배터리 모듈 |
| WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
| KR20230104617A (ko) | 2020-10-07 | 2023-07-10 | 드렌 바이오, 인크. | 항-덱틴-1 항체 및 이의 사용 방법 |
| JP2024504903A (ja) * | 2021-01-29 | 2024-02-02 | 中外製薬株式会社 | 細胞死が観察される組織において特異的に作用する分子 |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
| IL318992A (en) | 2022-05-02 | 2025-04-01 | Precirix N V | Cancer treatment through advance directives |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU632372B2 (en) | 1989-08-22 | 1992-12-24 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| GB0805159D0 (en) * | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| KR101661770B1 (ko) | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| EP2424560A4 (en) | 2009-03-23 | 2013-11-27 | Inst Medical W & E Hall | COMPOUNDS AND METHOD FOR MODULATING THE IMMUNE REACTION |
| PE20120630A1 (es) | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US20150132302A1 (en) | 2012-05-01 | 2015-05-14 | The University Of Sydney | Vaccine and uses thereof |
| CN113045660B (zh) | 2013-03-13 | 2023-09-01 | 伊麦吉纳博公司 | 与cd8的抗原结合构建体 |
| PL2992101T3 (pl) * | 2013-04-29 | 2019-05-31 | Agrosavfe Nv | Kompozycje agrochemiczne zawierające przeciwciała wiążące się ze sfingolipidami |
| ITTO20130563A1 (it) * | 2013-07-05 | 2015-01-06 | Savio Spa | Dispositivo per l'apertura e la chiusura di un'anta oscillante apribile verso l'esterno |
| CN105705641B (zh) | 2013-07-18 | 2021-07-13 | 弗拉芒区生物技术研究所 | 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 |
| JP6475712B2 (ja) | 2013-07-19 | 2019-02-27 | ヴィブ ブイゼットダブリュー | サイトカインアンタゴニストの標的化 |
| BR112016001114B1 (pt) | 2013-07-19 | 2023-02-14 | Vib Vzw | Composição compreendendo uma proteína de fusão e uso da referida composição |
| MX370348B (es) | 2013-07-19 | 2019-12-10 | Vib Vzw | Miembros de la familia il-1 modificados dirigidos. |
| US11273204B2 (en) | 2013-08-08 | 2022-03-15 | Cytune Pharma | IL-15 and IL-15RAPLHA sushi domain based immunocytokines |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2016187459A1 (en) * | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| EP3454887B1 (en) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CN110114368B (zh) * | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| WO2018144999A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019191519A1 (en) * | 2018-03-28 | 2019-10-03 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
-
2018
- 2018-08-08 CN CN202410087979.4A patent/CN117924493A/zh active Pending
- 2018-08-08 KR KR1020257010936A patent/KR20250049459A/ko active Pending
- 2018-08-08 KR KR1020207006788A patent/KR102659140B1/ko active Active
- 2018-08-08 MX MX2020001513A patent/MX2020001513A/es unknown
- 2018-08-08 CN CN201880065737.8A patent/CN111511764B/zh active Active
- 2018-08-08 SG SG11202001063QA patent/SG11202001063QA/en unknown
- 2018-08-08 CA CA3069992A patent/CA3069992A1/en active Pending
- 2018-08-08 JP JP2020507609A patent/JP7327885B2/ja active Active
- 2018-08-08 US US16/636,250 patent/US12091463B2/en active Active
- 2018-08-08 AU AU2018313810A patent/AU2018313810B2/en active Active
- 2018-08-08 WO PCT/US2018/045742 patent/WO2019032662A1/en not_active Ceased
- 2018-08-08 KR KR1020247012563A patent/KR102793204B1/ko active Active
- 2018-08-08 BR BR112020002706-5A patent/BR112020002706A2/pt unknown
- 2018-08-08 EP EP18844219.8A patent/EP3665303A4/en active Pending
-
2020
- 2020-02-06 IL IL272524A patent/IL272524A/en unknown
- 2020-02-06 MX MX2025009222A patent/MX2025009222A/es unknown
- 2020-02-06 MX MX2025009223A patent/MX2025009223A/es unknown
-
2023
- 2023-03-03 JP JP2023033005A patent/JP7559114B2/ja active Active
-
2024
- 2024-05-20 US US18/668,770 patent/US20240360224A1/en active Pending
- 2024-09-05 US US18/825,514 patent/US20250066486A1/en active Pending
- 2024-09-18 JP JP2024161448A patent/JP7746499B2/ja active Active
-
2025
- 2025-05-01 AU AU2025203121A patent/AU2025203121A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530302A5 (enExample) | ||
| US20240034802A1 (en) | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy | |
| JP7522156B2 (ja) | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 | |
| JP2020530298A5 (enExample) | ||
| Klener et al. | Immunotherapy approaches in cancer treatment | |
| Campoli et al. | Immunotherapy of malignant disease with tumor antigen–specific monoclonal antibodies | |
| US20170022273A1 (en) | Antibody therapeutics that bind lag3 | |
| JP2018536431A (ja) | キメラ抗原受容体および使用方法 | |
| TW202206453A (zh) | 表現嵌合抗原受體之病毒特異性免疫細胞 | |
| JP2020537503A (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| JP7677908B2 (ja) | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 | |
| US20220235134A1 (en) | Anti-b7-h3 antibodies | |
| EP3746103A1 (en) | Engineered proteins to enhance sensitivity of a cell to il-2 | |
| US11795221B2 (en) | Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof | |
| WO2019109838A1 (zh) | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 | |
| CN109929037B (zh) | 针对程序性死亡配体的结合物及其应用 | |
| US20240075142A1 (en) | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy | |
| JP2025525535A (ja) | 三重特異性抗体及びその使用 | |
| CN115666724A (zh) | 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法 | |
| US20250009879A1 (en) | Natural killer cell-specific chimeric antigen receptor and use thereof | |
| WO2024192017A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2024530656A (ja) | 新規Ｔｉｍ－４結合剤の作製及び特性決定 | |
| JP2023542490A (ja) | Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法 | |
| CN118480130A (zh) | 靶向msln的抗体、嵌合抗原受体及其应用 |